PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation

References

• O'Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol 2016; 13:691-706; PMID:27848961; https://doi.org/10.1038/nrgastro.2016.165
   PubMed Web of Science ®Google Scholar
• Wang J, Qian J, Hu Y, Kong X, Chen H, Shi Q, Jiang L, Wu C, Zou W, Chen Y et al. ArhGAP30 promotes p53 acetylation and function in colorectal cancer. Nat Commun 2014; 5:4735; PMID:25156493; https://doi.org/10.1038/ncomms5735
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017; 67(3):177-93; PMID:28248415; https://doi.org/10.3322/caac.21395
   PubMed Web of Science ®Google Scholar
• Bever KM, Le DT. An expanding role for immunotherapy in colorectal cancer. J Natl Compr Cancer Netw 2017; 15:401-10; PMID:28275038; https://doi.org/10.6004/jnccn.2017.0037
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016; 16:275-87; PMID:27079802; https://doi.org/10.1038/nrc.2016.36
   PubMed Web of Science ®Google Scholar
• Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015; 520:368-72; PMID:25807485; https://doi.org/10.1038/nature14336
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; https://doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 2015; 162:1271-85; PMID:26359985; https://doi.org/10.1016/j.cell.2015.07.061
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang C, Liu X, Wang Z, Sun L, Li G, Liang J, Hu H, Liu Y, Zhang W et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology 2016; 5:e1196310; PMID:27999734; https://doi.org/10.1080/2162402X.2016.1196310
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; https://doi.org/10.1056/NEJMoa1500596
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; https://doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Tan S, Zhang CWH, Gao GF. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Targeted Ther 2016; 1:16029; https://doi.org/10.1038/sigtrans.2016.29
   PubMed Web of Science ®Google Scholar
• Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology 2016; 5:e1235107; PMID:27999753; https://doi.org/10.1080/2162402X.2016.1235107
   PubMed Web of Science ®Google Scholar
• Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Targeted Ther 2016; 1:16030; https://doi.org/10.1038/sigtrans.2016.30
   Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to Anti–PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; https://doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; https://doi.org/10.1158/1078-0432.CCR-13-3271
   PubMed Web of Science ®Google Scholar
• Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL, Hu J, Liu B et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PloS One 2013; 8:e65821; PMID:23785454; https://doi.org/10.1371/journal.pone.0065821
   PubMed Web of Science ®Google Scholar
• Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Modern Pathol 2016; 29:1104-12; PMID:27198569; https://doi.org/10.1038/modpathol.2016.95
   PubMed Web of Science ®Google Scholar
• Inaguma S, Lasota J, Wang Z, Felisiak-Golabek A, Ikeda H, Miettinen M. Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. Modern Pathol 2017; 30:278-85; PMID:27813511; https://doi.org/10.1038/modpathol.2016.185
   PubMed Web of Science ®Google Scholar
• Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014; 38:1715-23; PMID:25025450; https://doi.org/10.1097/PAS.0000000000000297
   PubMed Web of Science ®Google Scholar
• Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ et al. Epithelial PD-L2 expression marks Barrett's esophagus and esophageal adenocarcinoma. Cancer Immunol Res 2015; 3:1123-9; PMID:26081225; https://doi.org/10.1158/2326-6066.CIR-15-0046
   PubMed Web of Science ®Google Scholar
• Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010; 138:958-68; PMID:19914252; https://doi.org/10.1053/j.gastro.2009.11.005
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun 2016; 7:12632; PMID:27572267; https://doi.org/10.1038/ncomms12632
   PubMed Web of Science ®Google Scholar
• Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant 2007; 7:2683-92; PMID:17924994; https://doi.org/10.1111/j.1600-6143.2007.01999.x
   PubMed Web of Science ®Google Scholar
• Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, Brousset P, Bidaut A, Ycart B, Fournié JJ. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology 2015; 4:e1026530; PMID:26405585; https://doi.org/10.1080/2162402X.2015.1026530
   PubMed Web of Science ®Google Scholar
• Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov 2017; 3:17004; PMID:28280600; https://doi.org/10.1038/celldisc.2017.4
   PubMed Web of Science ®Google Scholar
• Hickmott L, De La Pena H, Turner H, Ahmed F, Protheroe A, Grossman A, Gupta A. Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature. Targeted Oncol 2017; 12(2):235-41; PMID:28255845; https://doi.org/10.1007/s11523-017-0480-y
   PubMed Web of Science ®Google Scholar
• Rao M, Valentini D, Dodoo E, Zumla A, Maeurer M. Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. Int J Infect Dis 2017; 56:221-8; PMID:28163164; https://doi.org/10.1016/j.ijid.2017.01.028
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, Hua P, Duke-Cohan JS, Umetsu DT, Sharpe AH et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med 2014; 211:943-59; PMID:24752301; https://doi.org/10.1084/jem.20130790
   PubMed Web of Science ®Google Scholar
• Mahalingam J, Lin YC, Chiang JM, Su PJ, Fang JH, Chu YY, Huang CT, Chiu CT, Lin CY. LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. Clin Cancer Res 2012; 18:5224-33; PMID:22879386; https://doi.org/10.1158/1078-0432.CCR-12-0211
   PubMed Web of Science ®Google Scholar
• Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology 2012; 142:562-71 e2; PMID:22115830; https://doi.org/10.1053/j.gastro.2011.11.026
   PubMed Web of Science ®Google Scholar
• Croken MM, Qiu W, White MW, Kim K. Gene set enrichment analysis (GSEA) of toxoplasma gondii expression datasets links cell cycle progression and the bradyzoite developmental program. BMC Genom 2014; 15:515; PMID:24962434; https://doi.org/10.1186/1471-2164-15-515
   PubMed Web of Science ®Google Scholar